$2.78
▲ +1.2% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
How Cabaletta Bio (CABA) Is Turning Rese-cel Enrollment and New Financing Into a Clearer Autoimmune Cell Therapy Setup
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
Cabaletta Bio's Rese-cel Shows Potential in Treating Autoimmune Diseases
Overview
52-week range
$1.26
$4.23
51% of range
Avg surprise (last 3)
-1.3%
Avg reaction (last 2)
+19.9%
100% positive
Latest IV / EM
87%
EM ±20.0% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.39 | $-0.41 | +4.9% | +45.1% | +0.6% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.44 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.73 | $-0.71 | -2.8% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.71 | $-0.67 | -6.0% | — | +39.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.62 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.56 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.51 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.37 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.37 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.37 | -$0.73 | +49.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-44M | — | $-47M | $-46M | $-37M | — | $-33M | $-30M |
| Net income | $-44M | — | $-45M | $-45M | $-36M | — | $-31M | $-28M |
| EPS (diluted) | $-0.39 | — | $-0.44 | $-0.73 | $-0.71 | — | $-0.62 | $-0.56 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $117M | $83M | $60M | $146M | $132M | $164M | $171M | $179M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $122M | $139M | $165M | $198M | $135M | $167M | $186M | $206M |
| Total assets | $148M | $165M | $190M | $224M | $165M | $185M | $204M | $217M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $45M | $53M | $50M | $46M | $44M | $33M | $30M | $18M |
| Total equity | $103M | $112M | $139M | $178M | $122M | $152M | $174M | $200M |